Released on: January 23, 2008, 12:52 am

Press Release Author: Bharat Book Bureau

Industry: Healthcare

Press Release Summary: Increasingly the large pharmaceutical companies are pumping
money and ambition into the DNA/RNA therapy market. Whether its through forming
collaboration/licensing agreements, or acquiring smaller companies they can see the
financial opportunities. In particular the large pharmaceutical companies Pfizer,
Sanofi-Aventis, Eli Lilly & Company and Merck & Co all have substantial investment
in the RNA/DNA therapy products market. With Merck & Co in particularly showing its
faith in the future potential of this market by taking the gamble of acquiring the
specialist RNAi company Sirna, towards the end of 2006.

Press Release Body: This interest reflects the advances being made in this sector
and implies that it is eventually on the verge of success. The investment of these
larger companies makes that success both more likely to occur and more likely to
occur quickly. The vast potential of RNA/DNA therapies to treat the cause of disease
across many therapeutic areas is set to be realized.

Report focuses on the commercial and strategic opportunities within the human genome
project. It examines the companies utilizing novel molecular biological techniques
to try to exploit this knowledge to produce RNA/DNA products. The genetic
characterisation of many viruses is also leading to DNA and RNA products being used
to treat infectious disease, a therapeutic area for which traditional drug
development is difficult, as with the recent announcement regarding AIDS research.

It has been identified that 68 companies are actively involved in this field, 35 of
these companies are primarily focused on the development of RNA/DNA therapy products
and 33 companies are involved in collaborations.

This represents a substantial investment in the future of the RNA/DNA therapy
products market and over the forecast period this investment will begin to pay off.
There are 2 RNA/DNA therapy products due to submit licence applications in 2007,
with a further 67 products in clinical trials and a further 45 products in
pre-clinical development.

Of these products, 14 have the greatest potential both to be launched before 2012
and to make a contribution to this market. This would result in a substantial
increase in the RNA/DNA therapy product market over the forecast period and imply
that this sector is eventually achieving some of its anticipated potential.

There are many companies using established and novel molecular biological techniques
to try to produce successful RNA/DNA products for a variety of indications. However,
even with substantial investment, the RNA/DNA therapy products market is still in
its infancy, only three products have obtained a licence and only Macugen, for wet
AMD, is actively available on the worldwide markets. RNA/DNA therapy products have
faced problems, principally due to immunogenicity and in proving effective enough,
primarily due to inefficient delivery systems.

For more information kindly visit: http://www.bharatbook.com/detail.asp?id=52066

Web Site: http://www.bharatbook.com

Contact Details: Bharat Book Bureau
207, Hermes Atrium,
Sector 11, Plot No.57,
PO Box.54, CBD Belapur,
Navi Mumbai - 400 614, India.
Phone:+91-(022)-2757 8668 / 2757 9438
Fax:+91-(022)-2757 9131
E-mail: info@bharatbook.com